Research programme: plasminogen inhibitor - Bayer HealthCareAlternative Names: BAY
Latest Information Update: 14 Jan 2015
At a glance
- Originator Bayer HealthCare
- Class Small molecules
- Mechanism of Action Plasminogen activator inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Blood coagulation disorders
Most Recent Events
- 30 Sep 2014 Preclinical trials in Coagulation disorders in Germany (PO)